HeartSciences (HSCS) announces death of COO and director, affirms business plans

Rhea-AI Filing Summary

HeartSciences Inc. reported the death of Mark Hilz, its Chief Operating Officer, Corporate Secretary and a board member, who passed away on April 1, 2026 at age 67 after a period of illness. He had served on the Board since 2013 and as COO and Corporate Secretary since March 2022.

The company states it does not expect to hire a new Chief Operating Officer in the foreseeable future, noting that its MyoVista Insights™ software platform has been launched and the MyoVista® wavECG™ device has been submitted to the U.S. Food and Drug Administration for 510(k) premarket clearance. HeartSciences does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform as a result of his passing.

Insights

Corporate governance analyst

HeartSciences reports COO and director death, but affirms unchanged strategy.

HeartSciences Inc. disclosed that Chief Operating Officer, Corporate Secretary and director Mark Hilz died on April 1, 2026 after an illness. He had longstanding board tenure since 2013 and moved into the COO and Corporate Secretary roles in March 2022, giving him deep institutional knowledge.

The company indicates it does not plan to appoint a new Chief Operating Officer in the foreseeable future. It links this to the launch of its MyoVista Insights™ software platform and submission of the MyoVista® wavECG™ device for U.S. Food and Drug Administration 510(k) clearance in December 2025, suggesting key operational milestones are already in place.

HeartSciences explicitly states it does not anticipate changes to its business, operations or planned commercialization of the MyoVista Insights platform, including the MyoVista® wavECG™ submission, as a result of the loss. Future disclosures in company filings may clarify how responsibilities are distributed among remaining executives, but the current message emphasizes continuity.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Age of COO at death: 67 years Board tenure: Since 2013 COO and Corporate Secretary tenure: Since March 2022 +2 more

5 metrics

Age of COO at death 67 years Age of Mark Hilz at his passing on April 1, 2026

Board tenure Since 2013 Mark Hilz’s service as HeartSciences board member

COO and Corporate Secretary tenure Since March 2022 Start of Mark Hilz’s COO and Corporate Secretary roles

FDA submission date December 2025 MyoVista wavECG device submitted for 510(k) premarket clearance

Filing signature date April 3, 2026 Date Andrew Simpson signed on behalf of HeartSciences

Key Terms

Emerging growth company, MyoVista Insights™, MyoVista® wavECG™, U.S. Food and Drug Administration, +1 more

5 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

MyoVista Insights™ technical

"As the MyoVista Insights™ software platform has now been launched"

MyoVista® wavECG™ technical

"and the MyoVista® wavECG™ has been submitted for the U.S. Food and Drug Administration"

U.S. Food and Drug Administration regulatory

"submitted for the U.S. Food and Drug Administration (“FDA”) clearance"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

510(k) premarket clearance regulatory

"originally submitted to the FDA in December 2025 for 510(k) premarket clearance"

A 510(k) premarket clearance is a U.S. Food and Drug Administration process that lets a medical device be marketed after the maker shows it is similar in intended use and basic technology to an already approved device. It matters to investors because clearance is usually faster and less expensive than full approval, reducing regulatory risk and allowing a product to reach customers and generate revenue sooner — like passing a required inspection before opening a new store.

Understanding 8-K Material Events →

false 0001468492 0001468492 2026-04-01 2026-04-01 0001468492 us-gaap:CommonStockMember 2026-04-01 2026-04-01 0001468492 HSCS:WarrantsMember 2026-04-01 2026-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

Texas		001-41422		26-1344466
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

550 Reserve Street, Suite 360
Southlake, Texas		76092
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (682) 237-7781

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		HSCS		The NASDAQ Stock Market LLC
Warrants		HSCSW		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a)(b) On April 1, 2026, Mark Hilz, Chief Operating Officer, Corporate Secretary and member of the Board of Directors of HeartSciences Inc. (the “Company”) passed away at the age of 67, following a period of illness. Mr. Hilz served as a member of the Company’s Board of Directors since 2013 and as its Chief Operating Officer and Corporate Secretary since March 2022.

The Company mourns the loss of Mr. Hilz, an esteemed colleague, visionary and friend, and extends its sincere condolences to his family and loved ones.

As the MyoVista Insights™ software platform has now been launched and the MyoVista® wavECG™ has been submitted for the U.S. Food and Drug Administration (“FDA”) clearance, the Company does not anticipate hiring a new Chief Operating Officer or replacing the role in the foreseeable future. The Company does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform, including its MyoVista® wavECG™ device submission to the FDA originally submitted to the FDA in December 2025 for 510(k) premarket clearance, as a result of Mr. Hilz’s passing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HeartSciences Inc.
Date: April 3, 2026	By:	/s/ Andrew Simpson
	Name: Title:	Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

2

FAQ

What did HeartSciences (HSCS) disclose about its leadership on April 1, 2026?

HeartSciences disclosed that Chief Operating Officer, Corporate Secretary and board member Mark Hilz passed away on April 1, 2026 at age 67. He had served on the Board since 2013 and as COO and Corporate Secretary since March 2022.

Will HeartSciences (HSCS) appoint a new Chief Operating Officer after Mark Hilz’s passing?

HeartSciences stated it does not anticipate hiring a new Chief Operating Officer or replacing that role in the foreseeable future. The company links this decision to the launch of its MyoVista Insights software platform and the MyoVista wavECG device’s FDA submission.

How long did Mark Hilz serve HeartSciences (HSCS) as a director and officer?

Mark Hilz served as a member of HeartSciences’ Board of Directors since 2013 and as Chief Operating Officer and Corporate Secretary since March 2022. The company described him as an esteemed colleague, visionary and friend, and expressed condolences to his family.

Does HeartSciences (HSCS) expect business changes due to Mark Hilz’s death?

HeartSciences stated it does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform as a result of his passing. This includes no anticipated changes to the MyoVista wavECG device submission to the U.S. Food and Drug Administration.

What products did HeartSciences (HSCS) highlight in connection with the leadership change?

HeartSciences highlighted its MyoVista Insights software platform, which has been launched, and its MyoVista wavECG device. The company noted that the device was submitted to the U.S. Food and Drug Administration in December 2025 for 510(k) premarket clearance.

Who signed the HeartSciences (HSCS) report announcing Mark Hilz’s passing?

The report was signed by Andrew Simpson, President, Chief Executive Officer and Chairman of the Board of Directors of HeartSciences. His signature appears on behalf of the company pursuant to the Securities Exchange Act of 1934 requirements.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.4 KB
• EX-101 XBRL DEFINITION FILE 25.9 KB
• EX-101 XBRL LABEL FILE 35.6 KB
• EX-101 XBRL PRESENTATION FILE 24.6 KB